

## RESOURCES

### PEOPLE

Genomica Corp. (Boulder, CO) has appointed **Teresa W. Ayers** chief executive officer and director. Thomas G. Marr, who founded the company, retains his positions as president, chief scientist, and director. Ms. Ayers was most recently president and CEO of BioStar Inc.

ArQule (Medford, MA) has announced the appointment of **Philippe Bey** to the positions of chief scientific officer and senior vice president of research and development, succeeding Joseph C. Hogan, Jr., who resigned in July to pursue other business interests. Dr. Hogan will continue to serve as chairman of the board in a nonexecutive capacity until the fourth quarter of 1999. Dr. Bey joins ArQule from Hoechst Marion Roussel, where he was senior vice president, US R&D.



**Thomas Beck** has been named to the newly created position of president and director, global research of UCB Research (Cambridge, MA), a division of UCB Pharma. Previously, Dr. Beck was president and CEO of CytoMed, which was acquired by UCB Pharma in October 1998.

Amylin Pharmaceuticals (San Diego, CA) has announced the election of **Vaughn D. Bryson**, the former president and CEO of Eli Lilly and Co., to its board of directors. Mr. Bryson was vice chairman of Vector Securities International from 1994 to 1996, after a 32-year career at Lilly.

**Taylor J. Crouch** has been appointed president and CEO of Variagenics (Cambridge, MA), replacing **Fred Ledley**. Mr. Crouch was most recently senior vice president, worldwide marketing and strategic development at Parexel. Dr. Ledley will continue to work with the company as a principal scientific adviser. In addition, the company announced the appointment of **Philippe Chambon** to its board of directors. Dr. Chambon is general partner of The Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette, which led a recently completed \$19 million round of financing for Variagenics.

Oxagen (Oxford, UK) has announced the appointment of **Peter Doyle** to its board of directors. Dr. Doyle spent more than 35 years at ICI and Zeneca, most recently as executive director of Zeneca Group until his retirement this past June.

**Alistair Duncan** has been named president and CEO of Chromos Molecular Systems (Burnaby, BC, Canada). One of the company's founders, he has served as COO and as a director, and, most recently, as interim president and CEO.

**Adrian Hennah** has been elected to the Affymetrix (Santa Clara, CA) board of directors. Mr. Hennah, currently serving as senior vice president and CFO of Glaxo Wellcome, will replace Douglas Hurt as one of Glaxo's two nominees to serve on Affymetrix's board.

Chiron (Emeryville, CA) has named **Peder K. Jensen** corporate vice president and head of development, a newly created position. Most recently, he was development director, chief medical officer, and a member of the board of British Biotech plc, as well as president of British Biotech, Inc. Chiron also announced the appointment of **Joyce A. Lonergan**, most recently a director and operating partner at Vector Fund Management, as division vice president of corporate development.

Former FDA commissioner and president emeritus of Stanford University **Donald Kennedy** has been elected to the board of directors at CytoTherapeutics (Lincoln, RI). The appointment brings the number of board members to seven.

Nanogen (San Diego, CA) has announced the promotions of **Harry J. Leonhardt** to senior vice president, general counsel and secretary and **Kieran Gallahue** to vice president and CFO. Previously, Mr. Leonhardt was vice president, general counsel and secretary, and Mr. Gallahue was vice president strategic marketing.

Inhale Therapeutic Systems (San Carlos, CA) has named **Brigid Makes** as vice president of finance and administration and CFO, following the resignation of Judi Lum. Ms. Makes most recently served as vice president, CFO, and treasurer at OraVax.

Geron (Menlo Park, CA) has appointed **Thomas B. Okarma** president and CEO, succeeding Ronald W. Eastman, who will remain on the board of directors. Dr. Okarma joined Geron in 1997 as vice president of R&D.

**Michael M. Wick**, president and COO of Telik (S. San Francisco, CA), has been promoted to president and CEO. Former chief executive Clifford Orent remains Telik's chairman of the board.